Purple Biotech to sell 2.7M American Depositary Shares, warrants

Purple Biotech has filed to sell 2.7 million American Depositary Shares and warrants. H.C. Wainwright & Co. is acting as the manager for the sale. The move aims to raise funds for the company's operations and growth plans.

Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage biotechnology company focused on developing first-in-class therapies for tumor immune evasion and drug resistance, has announced its intention to sell 2.7 million American Depositary Shares (ADS) and warrants. The move is aimed at raising funds to support the company's ongoing operations and growth plans. H.C. Wainwright & Co. is acting as the manager for the sale.

The company's CEO, Gil Efron, will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, in New York City. This event provides an opportunity for investors to gain insights into Purple Biotech's pipeline and strategic plans. The fireside chat is set for September 10, 2025, at 11:30 AM ET.

Purple Biotech's pipeline includes CAPTN-3, CM24, and NT219. CAPTN-3 is a preclinical platform of conditionally activated tri-specific antibodies that engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. CM24 is a humanized monoclonal antibody that blocks CEACAM1, supporting tumor immune evasion and survival through multiple pathways. NT219 is a dual inhibitor that targets IRS1/2 and STAT3, with demonstrated anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

The sale of ADS and warrants is a strategic move for Purple Biotech to secure additional capital for its research and development efforts, as well as to expand its clinical trials and commercialization plans. The company's headquarters are located in Rehovot, Israel.

References:
[1] https://www.stocktitan.net/news/PPBT/purple-biotech-to-participate-in-the-h-c-wainwright-27th-annual-5bm0ey4icnik.html
[2] https://www.ainvest.com/news/realpha-strategic-momentum-ai-driven-real-estate-disruption-investor-access-wainwright-2508/